Kura Oncology (Nasdaq: KURA) will report its second quarter 2026 financial results after the close of U.S. financial markets on Wednesday, August 12, 2026. Management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss results and provide a corporate update.
The live webcast and archived replay will be available on Kura’s website under the Investors > Events and Presentations section. Kura is a biopharmaceutical company focused on precision medicines for cancer, including KOMZIFTI (ziftomenib), an FDA-approved, once-daily oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
KURA's prior earnings-date notices were followed by 0.43% and 1.05% 24-hour moves, providing a narro...
Analysis
KURA's prior earnings-date notices were followed by 0.43% and 1.05% 24-hour moves, providing a narrow historical comparison. Recent Net Selling and moderate short positioning remain relevant risk factors.
Prior notice preceded a 1.05% 24-hour move after announcing fourth-quarter and full-year results timing.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Tag-specific history showed positive 24-hour reactions of 0.43% and 1.05% after prior earnings-date announcements.
Key Terms
small molecule drug candidates, menin inhibitor, NPM1-mutated acute myeloid leukemia, farnesyl transferase inhibition
4 terms
small molecule drug candidatestechnical
"Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways"
Small molecule drug candidates are low‑molecular‑weight chemical compounds designed to bind to specific biological targets in the body and change how those targets work; they are typically made by chemical synthesis and often can be taken as pills or small injectables. For investors, they matter because their progress through research, testing and approval drives a drug developer’s potential future sales and value—think of them as prototype keys being tested to fit molecular locks, where success or failure changes a company’s prospects.
menin inhibitormedical
"the FDA-approved once-daily, oral menin inhibitor for the treatment of adults"
A menin inhibitor is a type of experimental drug that blocks the action of a protein called menin, which some cancers use to keep growing. Think of it as flipping off a switch that cancer cells rely on to survive; by doing so, these drugs can slow or stop tumor growth. Investors watch menin inhibitors because clinical trial results, regulatory approvals, and market demand determine whether they become valuable cancer treatments and potential revenue drivers.
NPM1-mutated acute myeloid leukemiamedical
"adults with relapsed or refractory NPM1-mutated acute myeloid leukemia"
A subtype of acute myeloid leukemia (AML) defined by a mutation in the NPM1 gene, which alters how blood-cell precursors behave and is detected by genetic testing. It matters to investors because the presence of this mutation affects prognosis, which patients are eligible for particular therapies or clinical trials, and therefore shapes drug development strategies, market size estimates, and regulatory pathways—similar to how a specific defect in a car model determines repair options and parts demand.
farnesyl transferase inhibitionmedical
"advancements in menin inhibition and farnesyl transferase inhibition"
Blocking the enzyme farnesyl transferase, which normally attaches a small lipid “farnesyl” tag to certain proteins so they can stick to cell membranes and send growth signals. Think of it like preventing a postage stamp from being added so a letter can’t be delivered to the right address. As a drug mechanism, it matters to investors because clinical trial outcomes, safety data, and regulatory decisions about these inhibitors can materially affect the value of companies developing them.
SAN DIEGO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report its second quarter 2026 financial results after the close of the U.S financial markets on Wednesday, August 12, 2026.
Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and provide a corporate update.
The live webcast and archived replay of the event may be accessed on the Company’s website at www.kuraoncology.com under the Investors tab in the Events and Presentations section.
About Kura Oncology Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us X and LinkedIn.
When will Kura Oncology (KURA) report its Q2 2026 financial results?
Kura Oncology will report its second quarter 2026 financial results on Wednesday, August 12, 2026, after the close of U.S. financial markets. According to Kura Oncology, the announcement will be followed by a webcast and conference call providing results discussion and a corporate update.
What time is Kura Oncology's Q2 2026 earnings conference call and webcast?
Kura Oncology’s Q2 2026 conference call and webcast will begin at 4:30 p.m. ET / 1:30 p.m. PT on August 12, 2026. According to Kura Oncology, management will review the financial results and deliver a broader corporate update during this event.
How can investors access Kura Oncology's Q2 2026 earnings webcast and replay?
Investors can access Kura Oncology’s live Q2 2026 webcast and archived replay on its website at kuraoncology.com under the Investors tab, in the Events and Presentations section. According to Kura Oncology, both live and replay access will be available online.
What does Kura Oncology (KURA) do in the precision oncology field?
Kura Oncology is a biopharmaceutical company focused on precision medicines for cancer, targeting key signaling pathways. According to Kura Oncology, its small molecule pipeline addresses high-need hematologic malignancies and solid tumors, emphasizing menin inhibition and farnesyl transferase inhibition strategies in oncology treatment.
What is KOMZIFTI (ziftomenib) developed by Kura Oncology?
KOMZIFTI (ziftomenib) is an FDA-approved, once-daily oral menin inhibitor developed and commercialized by Kura Oncology. According to Kura Oncology, it is indicated for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, reflecting the company’s precision medicine approach in hematologic cancers.
Where can investors find more information or contact Kura Oncology investor relations?
Investors can find more information on Kura Oncology at kuraoncology.com and follow the company on X and LinkedIn. According to Kura Oncology, investor and media inquiries can be directed to Greg Mann at 858-987-4046 or gmann@kuraoncology.com.
